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HCV (STAT-C), wherein orally administered small molecules
can provide targeted activity at speciﬁc points in the viral
life cycle. The ability to target speciﬁc steps of repli-
cation is apparent in the myriad of novel therapies in
research, such as protease inhibitors, nucleoside and non-
nucleoside polymerase inhibitors, glucosidase Inhibitors,
inosine monophosphate dehyrogenase (IMPDH) inhibitors,
and immune modulators (Interferons and their inducers,
toll-like receptor analogues, therapeutic vaccines). Combi-
nation therapies with new small molecules and peg-INF with
or without ribavirin are currently being evaluated. One of
the challenges of STAT-C therapy would be the prevention of
the evolution of drug resistance while enhancing tolerabil-
ity, decreasing treatment duration, and ultimately achieving
higher sustained virologic response rates.
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Liver complications have emerged as an important cause of
hospitalization and mortality among HIV-infected persons.1
Anti-HCV treatment offers the opportunity to eradicate HCV,
reduce the risk of disease progression and reduce liver-
related deaths. These beneﬁts are signiﬁcant and provide
the justiﬁcation for consideration of HCV treatment in every
HIV-HCV coinfected patient. However, since treatment is not
uniformly effective and is associated with side effects in the
majority of treated patients, the decision to proceed with
treatment requires a careful weighing of risk and beneﬁts
for each patient.
Patients should be on a stable ART regimen for at least
3 months prior to starting HCV treatment. Didanosine (DDI)
is absolutely contraindicated due to high risk of toxicity.2
Stavudine (D4T) and abacavir are relative contraindicated
due to interactions with ribavirin. AZT increases the risk of
anemia and should be avoided if possible.
The treatment of choice is peginterferon alfa (peg-IFN)
and weight-based ribavirin (1000mg daily if <75 kg and
1200mg daily if >75 kg).3 Weight-based ribavirin is recom-
mended for all genotypes, due to the higher rate of relapse
in HCV-HIV coinfected patients compared with HCV monoin-
fected patients. The dose of peginterferon alfa-2a is 180 ug
weekly and of peginterferon alfa-2b is 1.5 ug/kg weekly. The
duration of treatment is 24—48 weeks for genotypes 2 and
3 and 48—72 weeks for genotype 1, 4—6, with the time to
loss of HCV determining the length of treatment. Early viral
kinetics strongly inﬂuences duration of therapy. Shorter
duration may be a consideration in patients achieving a
rapid virologic response (RVR), deﬁned as undetectable HCV
RNA at week 4 of treatment. Longer duration therapy (up to
72 weeks) is a strong consideration in ‘‘slow responders’’.
The most consistently identiﬁed pre-treatment predictors
of SVR are HCV viral load and HCV genotype.4—7 Adherence
is an important factor in achieving SVR in HCV-monoinfected
patients but data in coinfected patients is more
limited.
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Patients labeled as non-responders need to be carefully
valuated to identify those that may beneﬁt from retreat-
ent using optimal doses and duration of current therapies.
he available data indicate that subjects who failed a prior
ourse of suboptimal therapy may achieve SVR but at rates
ower than treatment-naive patients.8 Overall, the chance
VR in previously treated patients is dependent upon the
fﬁcacy of the previous tried regimen.
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IV infected subjects often have a multitude of metabolic
efects. The clinical outcomes associated with these
bnormalities include lipodystrophy, insulin resistance, dys-
ipidemia, nonalcoholic fatty liver disease, accelerated
therosclerosis with both coronary artery disease (CAD)
nd peripheral vascular disease. The development of these
omplications reﬂect a complex interaction between the
atient, the HIV virus, other concomitant infections and
AART therapy. The seriousness of these complications is
nderscored by the rising mortality from non-HIV related
auses in infected subjects. This is particularly important
n males >55 yrs of age where CAD is the leading cause
f death. Subjects with HIV infection are at increased risk
or myocardial infarction and this risk is related to the
se of protease inhibitors (PI). It is however important to
ote that conventional risk factors e.g. smoking are more
mportant determinants of cardiovascular outcomes rather
